These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26316014)

  • 21. Modeling and optimization of combined cytostatic and cytotoxic cancer chemotherapy.
    Villasana M; Ochoa G; Aguilar S
    Artif Intell Med; 2010 Nov; 50(3):163-73. PubMed ID: 20620035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A history of cancer chemotherapy.
    DeVita VT; Chu E
    Cancer Res; 2008 Nov; 68(21):8643-53. PubMed ID: 18974103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug delivery to tumours: recent strategies.
    Reddy LH
    J Pharm Pharmacol; 2005 Oct; 57(10):1231-42. PubMed ID: 16259751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Array of translational systems pharmacodynamic models of anti-cancer drugs.
    Ait-Oudhia S; Mager DE
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):549-565. PubMed ID: 27771815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mathematical modeling of ovarian cancer treatments: sequencing of surgery and chemotherapy.
    Kohandel M; Sivaloganathan S; Oza A
    J Theor Biol; 2006 Sep; 242(1):62-8. PubMed ID: 16580022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational oncology--mathematical modelling of drug regimens for precision medicine.
    Barbolosi D; Ciccolini J; Lacarelle B; Barlési F; André N
    Nat Rev Clin Oncol; 2016 Apr; 13(4):242-54. PubMed ID: 26598946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mathematical approaches to optimization of cancer chemotherapy.
    Zietz S; Nicolini C
    Bull Math Biol; 1979; 41(3):305-24. PubMed ID: 465827
    [No Abstract]   [Full Text] [Related]  

  • 28. [History and significance of sensitivity test of anticancer drugs].
    Taguchi T
    Gan To Kagaku Ryoho; 1982 Apr; 9(4):570-4. PubMed ID: 7184413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs.
    Usher JR; Henderson D
    IMA J Math Appl Med Biol; 1996 Jun; 13(2):99-126. PubMed ID: 8671582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptosis and cancer chemotherapy.
    Chresta CM; Arriola EL; Hickman JA
    Behring Inst Mitt; 1996 Oct; (97):232-40. PubMed ID: 8950479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer chemotherapy in the era of targeted therapy.
    Michael A; Syrigos K; Pandha H
    Prostate Cancer Prostatic Dis; 2009; 12(1):13-6. PubMed ID: 18521103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort.
    Michor F; Beal K
    Cell; 2015 Nov; 163(5):1059-1063. PubMed ID: 26590416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis.
    Savage P
    BMC Cancer; 2016 Nov; 16(1):906. PubMed ID: 27871274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Pathways: Targeting Cancer Stem Cells Awakened by Chemotherapy to Abrogate Tumor Repopulation.
    Chan KS
    Clin Cancer Res; 2016 Feb; 22(4):802-6. PubMed ID: 26671994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers.
    Dawar S; Singh N; Kanwar RK; Kennedy RL; Veedu RN; Zhou SF; Krishnakumar S; Hazra S; Sasidharan S; Duan W; Kanwar JR
    Drug Discov Today; 2013 Dec; 18(23-24):1292-300. PubMed ID: 24055842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New targets and drugs in cancer chemotherapy.
    Szekeres T; Novotny L
    Med Princ Pract; 2002; 11(3):117-25. PubMed ID: 12138292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.
    Reiter RJ; Rosales-Corral SA; Tan DX; Acuna-Castroviejo D; Qin L; Yang SF; Xu K
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An integrated cellular and sub-cellular model of cancer chemotherapy and therapies that target cell survival.
    Cook AB; Ziazadeh DR; Lu J; Jackson TL
    Math Biosci Eng; 2015 Dec; 12(6):1219-35. PubMed ID: 26775858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.